O76074 (PDE5A_HUMAN) Homo sapiens (Human)

cGMP-specific 3',5'-cyclic phosphodiesterase UniProtKBInterProSTRINGInteractive Modelling

875 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

46 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with 3-isobutyl-1-methylxanthine… Heteromer
P18545; P51160;
537-859
100ZN;MG;IBM;
Crystal structure of GAFb from the human phosphodiesterase 5homo-4-mer346-509
100.0
crystal structure of unliganded PDE5A GAF domainhomo-2-mer98-518
99.74
Crystal structure of PDE5A GAF domain (89-518)homo-2-mer101-518
99.73
Crystal structure of Human Phosphodiesterase 5 complexed with tadalafil(Cialis)homo-2-mer537-860
100.0ZN;MG;CIA;
Catalytic Domain Of Human Phosphodiesterase 5Amonomer534-862
100.0ZN;PO4;CIT;
Crystal structure of PDE5A1 in complex with icarisid IImonomer535-860
100ZN;MG;7CA;
Crystal structure of the catalytic domain of unliganded PDE5monomer535-860
100.0ZN;MG;
Crystal structure of PDE5 in complex with inhibitor 5Rmonomer535-860
100.0SO4;24E;ZN;MG;
Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitormonomer535-860
100.0ZN;MG;WAN;
Crystal structure of PDE5A1-IBMXmonomer535-860
99.68ZN;MG;IBM;
Crystal Structure of PDE5A1 catalytic domain in complex with Vardenafilmonomer535-860
100.0VDN;
Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitorsmonomer535-860
100.05EO;ZN;MG;
Crystal structure of PDE5 in complex with sildenafilmonomer535-860
100ZN;MG;VIA;
Crystal structure of PDE5 in complex with inhibitor LW1634monomer535-860
100.0ZN;MG;SO4;9M0;
Crystal structure of PDE5 in complex with inhibitor LW1805monomer535-860
100.0SO4;ZN;MG;9T9;
Catalytic Domain Of Human Phosphodiesterase 5A in Complex with Sildenafilmonomer534-858
94.77ZN;MG;VIA;GOL;
Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Tadalafilmonomer534-858
94.77ZN;MG;CIA;
Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Vardenafilmonomer534-858
94.77ZN;MG;VDN;
Crystal structure of PDE5A in complex with CVT-313monomer536-860
100.0MG;ZN;AJR;
Catalytic Domain Of Human Phosphodiesterase 5A in Complex with GMPmonomer534-858
94.77ZN;MG;5GP;
Crystal structure of PDE5A in complex with a novel inhibitormonomer536-860
100.0MG;ZN;B0C;
crystal structure of PDE5 in complex with a non-competitive inhibitormonomer535-859
100.0FZA;
Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitorsmonomer536-860
100.05CO;ZN;MG;
Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitorsmonomer536-860
100.05FO;ZN;MG;
Human PDE5 catalytic core in complex with avanafilmonomer536-859
100E6L;ZN;MG;SO4;
Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitorsmonomer535-858
100.05BA;ZN;MG;PEG;
Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitorsmonomer535-858
100.05BB;ZN;MG;
Crystal structure of PDE5A in complex with a novel inhibitormonomer536-859
100.0ZN;MG;VZF;
Crystal structure of Human Phosphodiesterase 5 complexed with Sildenafil(Viagra)monomer537-860
100.0ZN;MG;VIA;
Crystal structure of PDE5A complexed with its inhibitormonomer535-858
100.0PEG;ZN;MG;NI5;
Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitorsmonomer537-860
100.0ZN;MG;5IO;
Crystal structure of Human Phosphodiesterase 5 complexed with Vardenafil(Levitra)monomer537-860
100.0ZN;MG;VDN;
Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with sildenafilmonomer536-859
100ZN;MG;VIA;
Investigation of Aminopyridiopyrazinones as PDE5 Inhibitors: Evaluation of Modifications to the Cen…monomer536-858
100PD4;ZN;MG;
A novel series of potent and selective PDE5 inhibitor2monomer536-858
95.52ZN;MG;0H3;
Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitorsmonomer538-860
100.05BO;
A novel series of potent and selective PDE5 inhibitor1monomer536-858
94.43ZN;MG;TGE;
Crystal structure of PDE5A in complex with inhibitor L1monomer537-859
100.0ZN;MG;SO4;2OI;
Rational Design of Highly Selective PDE5 inhibitors for the Treatment of Idiopathic Pulmonary Fibro…monomer537-859
100.0WDB;ZN;MG;
Rational Design of Highly Selective PDE5 inhibitors for the Treatment of Idiopathic Pulmonary Fibro…monomer537-859
100.0WD3;ZN;MG;
Crystal structure of PDE5A in complex with inhibitor L12monomer537-859
100.0ZN;MG;2VI;
PDE5A for NaV1.7monomer537-858
94.41ZN;6LK;
Crystal structure of N2 substituted pyrazolo pyrimidinones - a flipped binding mode in PDE5monomer537-858
100ZN;MG;3P4;MES;
Identification, Synthesis, and SAR of Amino Substituted Pyrido[3,2b]pryaziones as Potent and Select…monomer537-858
100PD6;ZN;MG;
Crystal structure of PDE5A in complex with its inhibitormonomer537-858
100.0NI0;MG;PEG;ZN;

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3bjc.1.Amonomer0.82535-860
ZN;MG;WAN;99.89
3lfv.1.Ahomo-2-mer0.7398-518
99.76

2 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 23bjc.1.Amonomer0.82493-818
ZN;MG;WAN;99.88
Isoform 23lfv.1.Ahomo-2-mer0.7356-476
99.76